Altimmune ($ALT) Investment Analysis Report

2025-11-30
2025-11-23 21:54:10 (EST)

---

A Reddit discussion on r/Stocks (ticker: $ALT) framed Altimmune as a “last chance for under $5” investment, with conflicting perspectives:

• Bullish (Score:6):
  OP claimed ALT is undervalued, citing upcoming catalysts (48-week IMPACT trial data, FDA End-of-Phase 2 meeting) and 21% short interest as potential “rocket fuel.”
• Bearish (Score:1):
  A user warned that comparing ALT to billion-dollar acquired peers is premature without peer-reviewed 48-week data showing superior clinical benefit.
• Neutral (Score:1):
  Another user highlighted strong transparency via a 180-page Lancet publication of Phase 2b data (vs. typical <10 pages for peers).

The discussion emphasized awareness, not financial advice, and focused on ALT’s lead drug pemvidutide (GLP-1/glucagon agonist) for MASH, obesity, AUD, and ALD.

---

• Price Movement:
  ALT now trades at $5.26, above the OP’s $5 threshold, with a 1.74% gain on the latest close [0]. The stock has risen 22% over the past two weeks and 4 days consecutively [7].
• Analyst Sentiment:
  Wall Street analysts predict a 250.59% upside for ALT, with HC Wainwright boosting FY2025 EPS estimates [1].
• Sector Context:
  Big pharma’s M&A activity in the MASH/obesity space (Pfizer’s $5.2B Akero acquisition, Novo Nordisk’s $8.5B bid for Metsera) underscores the sector’s value [8,9].

• Catalyst Dependence:
  The 48-week IMPACT trial data (Q4 2025) and FDA End-of-Phase 2 meeting will determine Phase 3 design and investor confidence [4].
• Volatility:
  ALT exhibits high daily volatility (5-6% average true range) [6], making it sensitive to clinical/regulatory news.

---

Metric	Value	Source
Current Price	$5.26 (+1.74% daily)	[0]
Market Cap	$464.23M	[0]
52-Week Range	$2.90-$10.88	[0]
2-Week Gain	22.22%	[7]
Average Daily Volatility	~5-6%	[6]
Cash Reserves	$210.8M (9/30/25)	[4]
Upcoming Catalysts	48-week IMPACT data (Q4 2025), FDA End-of-Phase 2 meeting (Q4 2025)	[4,5]

---

• Direct:
  Altimmune ($ALT)
• Related Sectors:
  Biotech, Healthcare (MASH/obesity subsector)
• Peers:
  Akero Therapeutics (acquired by Pfizer for $5.2B), Metsera (Pfizer/Novo Nordisk bid), Viking Therapeutics [8,9]

---

1. Current Short Interest:
   The Reddit claim of 21% short interest lacks recent verification (no up-to-date data in tool outputs).
2. Exact Catalyst Timing:
   No specific date for 48-week data release or FDA meeting (only Q4 2025 guidance).
3. Peer Valuation Details:
   Limited data on how ALT’s Phase 2b results compare to acquired peers like Akero.

• Bullish:
  Undervaluation relative to sector M&A, strong Phase 2b MASH resolution data (58% vs. 20% placebo), and short squeeze potential [3,4].
• Bearish:
  Need 48-week data to confirm fibrosis improvement (Phase 2b missed this endpoint) and secure strategic partnerships [2].
• Neutral:
  Transparency via Lancet publication (180-page supplement) reduces information asymmetry [original Reddit post].

• 48-week IMPACT trial data release (Q4 2025)
• FDA End-of-Phase 2 meeting outcomes
• Short interest updates
• Peer comparison of clinical efficacy and valuation

---

1. Clinical Trial Risk:
   The 48-week data may not show meaningful fibrosis improvement, which is key for Phase 3 approval [2].
2. Regulatory Risk:
   The FDA may reject ALT’s Phase 3 design, delaying development [4].
3. Volatility Risk:
   ALT’s high daily volatility increases downside exposure to negative news [6].
4. Competition Risk:
   Big pharma’s deep pockets and advanced pipelines could overshadow ALT if its data is not best-in-class [8,9].

• “Users should be aware that clinical trial outcomes for pemvidutide are uncertain and may significantly impact ALT’s stock price.”
• “This development raises concerns about regulatory approval risk, as the FDA’s End-of-Phase 2 meeting could require additional data before Phase 3 initiation.”
• “Historical patterns suggest that biotech stocks with high volatility (like ALT) typically experience sharp price swings in response to clinical/regulatory news, which users should factor into their analysis.”

---

Disclaimer:

This report is for informational purposes only and does not constitute investment advice. Always conduct your own research before making financial decisions.

Compliance Note:

All data is sourced from verified tools and public domains as per the analysis framework.

Time Sensitivity:

This report reflects market conditions as of 2025-11-30 and may become outdated due to upcoming catalysts.